Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients—A Controlled Clinical Trial

Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients—A Controlled Clinical Trial

Background: This controlled clinical study aimed to investigate the impact of obesity on plasma and tissue pharmacokinetics of meropenem. Methods: Obese (body mass index (BMI) ≥ 35 kg/m<sup>2</sup>) and age-/sex-matched nonobese (18.5 kg/m<sup>2</sup> ≥ BMI ≤ 30 kg/m<sup&g...

Full description

Bibliographic Details
Main Authors:	Philipp Simon, David Petroff, David Busse, Jana Heyne, Felix Girrbach, Arne Dietrich, Alexander Kratzer, Markus Zeitlinger, Charlotte Kloft, Frieder Kees, Hermann Wrigge, Christoph Dorn
Format:	Article
Language:	English
Published:	MDPI AG 2020-12-01
Series:	Antibiotics
Subjects:	antibiotic dosing concentrations meropenem microdialysis obesity pharmacokinetics
Online Access:	https://www.mdpi.com/2079-6382/9/12/931

Similar Items

Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study
by: Philipp Simon, et al.
Published: (2020-04-01)

Comparison of Intravenous Microdialysis and Standard Plasma Sampling for Monitoring of Vancomycin and Meropenem Plasma Concentrations—An Experimental Porcine Study
by: Johanne Gade Lilleøre, et al.
Published: (2023-04-01)

Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics
by: David Busse, et al.
Published: (2021-08-01)

Concentrations of Co-Administered Meropenem and Vancomycin in Spinal Tissues Relevant for the Treatment of Pyogenic Spondylodiscitis—An Experimental Microdialysis Study
by: Josefine Slater, et al.
Published: (2023-05-01)

Tibial bone and soft-tissue concentrations following combination therapy with vancomycin and meropenem – evaluated by microdialysis in a porcine model <subtitle>should patients with open fractures have higher doses of antibiotics?</subtitle>
by: Sofus Ørbæk Vittrup, et al.
Published: (2022-02-01)

Population pharmacokinetics of meropenem in critically ill infant patients
by: Wanlika Yonwises, et al.
Published: (2021-10-01)

Effects of Meropenem on Patients with Ventilator-Induced Pneumonia in Intensive Care Unit
by: Taraneh Naghibi, et al.
Published: (2022-11-01)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
by: Eric Wenzler, et al.
Published: (2020-10-01)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
by: Gan Y, et al.
Published: (2023-06-01)

Free interstitial levels of metformin in the liver of healthy and diabetic Wistar rats
by: Andressa Braga, et al.
Published: (2022-06-01)

Evaluation of a Meropenem and Piperacillin Monitoring Program in Intensive Care Unit Patients Calls for the Regular Assessment of Empirical Targets and Easy-to-Use Dosing Decision Tools
by: Ferdinand Anton Weinelt, et al.
Published: (2022-06-01)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
by: Sonia Luque, et al.
Published: (2021-06-01)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
by: Ahmed A. Abulfathi, et al.
Published: (2021-06-01)

Meropenem pharmacokinetics during relapsing peritonitis due to ESBL‐producing Enterobacteriaciae in a liver transplant recipient
by: Kensuke Shoji, et al.
Published: (2019-11-01)

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis
by: Yue-E Wu, et al.
Published: (2022-12-01)

Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?
by: Silvia Corcione, et al.
Published: (2020-03-01)

Efficacy of Vancomycin and Meropenem in Central Nervous System Infections in Children and Adults: Current Update
by: Franziska Schneider, et al.
Published: (2022-01-01)

Evaluation of Meropenem Pharmacokinetics in an Experimental Acute Respiratory Distress Syndrome (ARDS) Model during Extracorporeal Membrane Oxygenation (ECMO) by Using a PenP β-Lactamase Biosensor
by: Max Andresen, et al.
Published: (2018-05-01)

Population PK/PD modelling of meropenem in preterm newborns based on therapeutic drug monitoring data
by: Sergey Zyryanov, et al.
Published: (2023-03-01)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
by: Renata Černá Pařízková, et al.
Published: (2021-07-01)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
by: Guoliang Deng, et al.
Published: (2023-03-01)

Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study
by: Hui-Ying Zhao, et al.
Published: (2017-01-01)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
by: Matthias Gijsen, et al.
Published: (2021-06-01)

Cerebrospinal Fluid Concentrations of Meropenem and Vancomycin in Ventriculitis Patients Obtained by TDM-Guided Continuous Infusion
by: Christoph Tiede, et al.
Published: (2021-11-01)

Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model
by: Yan Wang, et al.
Published: (2022-11-01)

Meropenem extraction by ex vivo extracorporeal life support circuits
by: Honeycutt Christopher Cole, et al.
Published: (2023-12-01)

PHARMACOKINETIC-PHARMACODYNAMIC CORRELATION FOR MEROPENEM APPLIED TO A BURN CHILD USING A BIOANALYTICAL LIQUID CROMATOGRAPHIC METHOD
by: Silvia R. C. J. Santos, et al.
Published: (2011-12-01)

Challenging T > MIC Using Meropenem vs. Escherichia coli and Pseudomonas aeruginosa
by: A. Nussbaumer-Pröll, et al.
Published: (2022-04-01)

Pharmacokinetic-Pharmacodynamic Correlation for Meropenem Applied to a Burn Child Using a Bioanalytical Liquid Cromatographic Method
by: Silvia R. C. J. Santos, et al.
Published: (2011-10-01)

Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing <i>K. pneumoniae</i> Septic Thrombosis Unresponsive to Ceftazidime/Avibactam: From the Bench to the Bedside
by: Alessandra Oliva, et al.
Published: (2021-06-01)

External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients
by: Nan Yang, et al.
Published: (2022-05-01)

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study
by: Stephan Braune, et al.
Published: (2018-01-01)

Population Pharmacokinetics of Continuous-Infusion Meropenem in Febrile Neutropenic Patients with Hematologic Malignancies: Dosing Strategies for Optimizing Empirical Treatment against Enterobacterales and <i>P. aeruginosa</i>
by: Pier Giorgio Cojutti, et al.
Published: (2020-08-01)

Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling
by: Soyoung Kang, et al.
Published: (2022-11-01)

Meropenem Induced Skin Drug Eruption in Infectious Mononucleosis: Immunological Phenomena or Non-immunological Phenomena?
by: Atousa Hakamifard, et al.
Published: (2020-01-01)

C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem
by: Yichang Zhao, et al.
Published: (2022-05-01)

Clinical pharmacokinetics of 3-h extended infusion of meropenem in adult patients with severe sepsis and septic shock: implications for empirical therapy against Gram-negative bacteria
by: Amol T. Kothekar, et al.
Published: (2020-01-01)

Combined Use of Vancomycin and Meropenem in Patient with Acute Intermittent Porphyria: A Case Report
by: İrfan ŞENCAN, et al.
Published: (2004-09-01)

Software- and TDM-Guided Dosing of Meropenem Promises High Rates of Target Attainment in Critically Ill Patients
by: Ute Chiriac, et al.
Published: (2023-06-01)

Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation
by: Jae Ha Lee, et al.
Published: (2021-11-01)